Your selection basket is empty.
Define a selection of ETFs which you would like to compare.
Add an ETF by clicking "Compare" on an ETF profile or by checkmarking an ETF in the ETF search.
| Index | Harbor Health Care |
| Investment focus | Equity, World, Health Care |
| Fund size | GBP 10 m |
| Total expense ratio | 0.89% p.a. |
| Replication | Physical (Full replication) |
| Legal structure | ETF |
| Strategy risk | Actively managed |
| Sustainability | No |
| Fund currency | USD |
| Currency risk | Currency unhedged |
| Volatility 1 year (in GBP) | 22.98% |
| Inception/ Listing Date | 4 April 2019 |
| Distribution policy | Accumulating |
| Distribution frequency | - |
| Fund domicile | Ireland |
| Fund Provider | HANetf |
| Fund Structure | Open-ended Investment Company (OEIC) |
| UCITS compliance | Yes |
| Administrator | J.P. Morgan Administration Services (Ireland) Limited |
| Investment Advisor | |
| Custodian Bank | J.P. Morgan SE - Dublin Branch |
| Revision Company | Ernst and Young |
| Fiscal Year End | 31 March |
| Swiss representative | Waystone |
| Swiss paying agent | Helvitsche Bank |
| Germany | 30% tax rebate |
| Switzerland | ESTV Reporting |
| Austria | Tax Reporting Fund |
| UK | UK Reporting |
| Indextype | Total return index |
| Swap counterparty | - |
| Collateral manager | |
| Securities lending | No |
| Securities lending counterparty |
| Ascendis Pharma A/S | 9.28% |
| Eli Lilly & Co. | 8.81% |
| Legend Biotech | 7.94% |
| AbbVie, Inc. | 6.10% |
| Masimo | 5.25% |
| UnitedHealth Group | 4.74% |
| Revolution Medicines | 4.53% |
| Vaxcyte | 4.46% |
| Natera | 3.85% |
| Rhythm Pharmaceuticals | 3.34% |
| United States | 81.39% |
| Ireland | 1.99% |
| Other | 16.62% |
| Health Care | 83.39% |
| Other | 16.61% |
| YTD | -4.22% |
| 1 month | -7.05% |
| 3 months | -3.08% |
| 6 months | +10.74% |
| 1 year | +0.53% |
| 3 years | -9.71% |
| 5 years | -33.14% |
| Since inception (MAX) | -4.22% |
| 2025 | +11.49% |
| 2024 | -7.81% |
| 2023 | -4.00% |
| 2022 | -21.47% |
| Volatility 1 year | 22.98% |
| Volatility 3 years | 19.85% |
| Volatility 5 years | 22.87% |
| Return per risk 1 year | 0.02 |
| Return per risk 3 years | -0.17 |
| Return per risk 5 years | -0.34 |
| Maximum drawdown 1 year | -19.76% |
| Maximum drawdown 3 years | -27.54% |
| Maximum drawdown 5 years | -46.90% |
| Maximum drawdown since inception | -46.90% |
| Listing | Trade Currency | Ticker | Bloomberg / iNAV Bloomberg Code | Reuters RIC / iNAV Reuters | Market Maker |
|---|---|---|---|---|---|
| gettex | EUR | W311 | - - | - - | - |
| Borsa Italiana | EUR | WELL | WELL IM WELLEUIV | WELL.MI WELLEURINAV=SOLA | RBC Europe Ltd |
| Euronext Paris | EUR | WELL | WELL FP WELLEUIV | WELP.PA WELLEURINAV=SOLA | RBC Europe Ltd |
| London Stock Exchange | GBX | WELP | WELP LN | WELP.L | RBC Europe Ltd |
| London Stock Exchange | USD | WELL | WELL LN | HAWELL.L | RBC Europe Ltd |
| London Stock Exchange | GBP | - | RBC Europe Ltd | ||
| SIX Swiss Exchange | CHF | WELL | WELL SW WELLEUIV | WELL.S WELLEURINAV=SOLA | RBC Europe Ltd |
| XETRA | EUR | W311 | W311 GY WELLEUIV | W311.DE WELLEURINAV=SOLA | RBC Europe Ltd |
| Fund name | Fund Size in m € (AuM) | TER p.a. | Distribution | Replication |
|---|---|---|---|---|
| iShares Healthcare Innovation UCITS ETF | 909 | 0.40% p.a. | Accumulating | Sampling |
| L&G Healthcare Technology & Innovation UCITS ETF USD Acc | 194 | 0.49% p.a. | Accumulating | Full replication |
| L&G Pharma Breakthrough UCITS ETF | 17 | 0.49% p.a. | Accumulating | Full replication |
| VanEck Genomics and Healthcare Innovators UCITS ETF A | 13 | 0.35% p.a. | Accumulating | Full replication |
| Xtrackers MSCI Genomic Healthcare Innovation UCITS ETF 1C | 6 | 0.30% p.a. | Accumulating | Full replication |